All compounds displayed nanomolar potency against the cancer-related hCA IX and hCA XII; moreover, they were shown to be devoid of any inhibitory activity toward the cytosolic hCA I and hCA II up to 10 μM concentration in the assay system. The gene discussed is CYP24A1; the disease is cancer.